Background
What do we already know about this topic?
- Patients often complain that current acute treatments for migraine take too long to provide pain relief, and relief isn’t lasting.
- Rimegepant is an orally-administered small molecule calcitonin gene-related peptide (CGRP) receptor antagonist that was recently approved by the FDA having demonstrated efficacy and safety in Phase 3 studies for the acute treatment of migraine.1,2
- Rimegepant 75 mg orally dissolving tablet (ODT) has a Tmax of 1.5 hours that may translate into early onset of action and a half-life of 10–12 hours, meaning it may provide a sustained effect in acute treatment.
How was this study conducted?
- Three Phase three, double-blind, randomized, placebo-controlled, multicenter trials of identical design were conducted in adults with a history of episodic migraine (N=3507).
- Subjects were randomized to receive rimegepant 75 mg tablet or 75 mg ODT (n=1749), or placebo (n=1758), and instructed to treat one migraine attack of moderate-to-severe pain intensity with a single dose of study medication.
- Coprimary endpoints were freedom from pain and most bothersome symptom (MBS) two hours post-dose.